NCT00070499 2026-03-18Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous LeukemiaNational Cancer Institute (NCI)Phase 2 Active not recruiting406 enrolled 11 charts